Mar 5, 2026 04:05PM
Feb 24, 2026 08:00AM
Feb 19, 2026 07:00AM
Feb 17, 2026 04:05PM
Feb 11, 2026 06:25AM
Feb 11, 2026 05:01AM
Feb 11, 2026 05:00AM Madrigal Expands its MASH Pipeline with Exclusive Global Licensing Agreement for Six Preclinical siRNA Programs
Feb 5, 2026 04:05PM
Feb 2, 2026 08:05AM
Jan 22, 2026 04:05PM
Jan 21, 2026 04:05PM
Jan 12, 2026 09:32AM
Jan 9, 2026 08:00AM
Jan 9, 2026 08:00AM Madrigal Expands its MASH Pipeline with Exclusive Global License Agreement for Ervogastat, a Phase 2 Oral DGAT-2 Inhibitor
Dec 18, 2025 04:05PM
Dec 15, 2025 04:05PM
Dec 4, 2025 04:05PM
Nov 20, 2025 04:05PM
Nov 20, 2025 04:02AM
Nov 17, 2025 08:00AM
Nov 10, 2025 08:02AM Madrigal reports positive two-year data for Rezdiffra in MASH cirrhosis patients
Nov 10, 2025 08:00AM
Nov 6, 2025 04:05PM
Nov 4, 2025 07:00AM
Oct 28, 2025 08:00AM
Oct 22, 2025 08:00AM
Oct 21, 2025 04:05PM
Oct 7, 2025 04:05PM Madrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4)
Sep 18, 2025 04:05PM
Sep 4, 2025 04:05PM
Sep 4, 2025 06:14AM
Sep 3, 2025 08:00AM
Aug 21, 2025 04:05PM
Aug 19, 2025 04:05PM
Aug 19, 2025 04:05PM Madrigal Receives European Commission Approval for Rezdiffra™ (resmetirom) for the Treatment of MASH with Moderate to Advanced Liver Fibrosis
Aug 12, 2025 05:22AM
Aug 11, 2025 08:00AM
Aug 7, 2025 04:05PM
Aug 5, 2025 07:00AM
Jul 30, 2025 05:00AM
Jul 30, 2025 05:00AM
Jul 25, 2025 08:00AM Madrigal Pharmaceuticals to Release Second-Quarter 2025 Financial Results and Host Webcast on August 5, 2025
Jul 22, 2025 08:00AM
Jul 22, 2025 08:00AM
Jul 16, 2025 04:05PM
Jul 16, 2025 02:48PM
Jul 16, 2025 08:02AM
Jul 16, 2025 08:00AM
Jun 20, 2025 06:31AM Madrigal Pharma (MDGL) Receives Positive CHMP Opinion for Resmetirom for the Treatment of MASH with Moderate to Advanced Liver Fibrosis
Jun 20, 2025 06:30AM

312,667 total articles have been posted to this entity.

Click Here to Sign-Up for StreetInsider.com Premium to View All